Pascal Soriot began as CEO of AstraZeneca in 2012, signing up with from a long profession in the pharmaceutical market, with stints as an executive at Roche and the biotech Genentech, where he led its acquisition by Roche.
Soriot, who trained as a vet and likewise has an MBA, infamously warded off an almost $120 billion takeover by Pfizer in 2014, intending to turn the business around on his own rather.
On pay, we’ll leave it to Soriot to inform it in his own words.
“The reality is I’m the lowest-paid CEO in the entire market,” he informed The Times of London last fall. “You understand, it is irritating to some degree. However at the end of the day, it is what it is.
“I am not going to grumble, however me and Emma [Walmsley, CEO of GlaxoSmithKline] are the most affordable paid in Europe and the United States.”
AstraZeneca’s market cap: $50 billion